Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient ...

Now may be an ideal time to buy stocks. Even if you don't have a lot of money that you can afford to invest, there are many ...

In the latest market close, Astrazeneca (AZN) reached $64.90, with a -1.35% movement compared to the previous day. The stock's change was more than the S&P 500's daily loss of 1.57%. Elsewhere, the ...

AstraZeneca Pharmaceuticals LP and a Christian sales specialist have agreed to settle his suit over the company’s failure to ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

As the countdown to the launch of its first therapeutic continues, Rocket Pharmaceuticals is fueling up its commercial team.